Regulatory Affairs
NAFDAC DG Presents Nigeria’s Regulatory Reforms as Model for Strengthening Medicines Regulation in Africa
NAFDAC Director-General Prof. Mojisola Adeyeye has presented Nigeria’s regulatory transformation at Harvard, highlighting the country’s progress in medicines regulation, digitalisation, laboratory capacity and efforts to strengthen pharmaceutical manufacturing.
The Director-General of the National Agency for Food and Drug Administration and Control (NAFDAC), Prof. Mojisola Adeyeye, has presented Nigeria’s regulatory reforms as a case study in strengthening medicines regulatory systems across Africa during an engagement at Harvard T.H. Chan School of Public Health in the United States.
Speaking at the Global Health Perspectives series organised by the Takemi Program in International Health, Adeyeye highlighted the institutional changes introduced at NAFDAC since 2017, including Nigeria’s advancement to World Health Organization (WHO) Maturity Level 3 (ML3) in medicines regulation.
She identified sustained institutional reforms, investment in scientific capabilities, effective enforcement and international collaboration as important elements in building a credible regulatory system capable of protecting public health.
Nigeria’s Progress in Medicines Regulation
A major focus of the presentation was NAFDAC’s progress under the WHO Global Benchmarking Tool (GBT), which assesses the performance and maturity of national regulatory authorities.
Nigeria achieved WHO Maturity Level 3 in March 2022, indicating that its regulatory system had attained a stable, well-functioning and integrated level. The achievement followed an earlier assessment that identified areas requiring institutional and regulatory improvements.
NAFDAC subsequently underwent a WHO re-benchmarking exercise and, on 30 June 2025, retained its ML3 status. The Agency described Nigeria as the first regulatory authority in Africa to successfully sustain the rating through the re-benchmarking process.
Maturity Level 4, the highest level under the WHO framework, and WHO-Listed Authority (WLA) status are among the Agency’s future regulatory objectives.
Five Pillars of Regulatory Transformation
Adeyeye outlined five strategic pillars underpinning NAFDAC’s institutional transformation:
1. Governance and institutional systems.
2. Scientific and quality capabilities.
3. Safety and quality of medical products.
4. Supply chain oversight and digitalisation.
5. Partnerships with industry and development partners.
According to the presentation, the reforms have contributed to several institutional milestones, including ISO 9001 certification, WHO prequalification of NAFDAC’s laboratory, expanded laboratory capacity and strengthened enforcement activities.
The Agency also reported that approximately 90 per cent of its regulatory processes have been digitised, reflecting efforts to improve operational efficiency, transparency and regulatory oversight.
Strengthening Pharmaceutical Manufacturing and Medicines Safety
The NAFDAC Director-General also highlighted the importance of strengthening local pharmaceutical manufacturing while maintaining rigorous quality and safety standards.
She emphasised that increasing domestic production should go hand in hand with effective regulatory oversight to ensure that locally manufactured medicines meet established quality requirements.
Adeyeye further stressed the importance of financial accountability, evidence-based decision-making, effective enforcement and strong institutional leadership in addressing the persistent threat posed by substandard and falsified medical products.
International partnerships and regulatory cooperation were also identified as important in improving regulatory capacity and supporting the harmonisation of standards across African countries.
Implications for Pharmaceutical Regulation in Africa
Nigeria’s regulatory progress has implications beyond its domestic pharmaceutical sector. A stable and internationally recognised regulatory system can strengthen confidence in locally manufactured medical products, support regulatory cooperation and improve opportunities for pharmaceutical trade across regional markets.
For African countries seeking to expand domestic pharmaceutical production and improve access to quality-assured medicines, the experience also highlights the importance of building strong regulatory institutions alongside manufacturing capacity.
The engagement at Harvard provided an opportunity to present Nigeria’s regulatory experience within a broader global health discussion. However, sustaining these gains will require continued investment in scientific infrastructure, regulatory workforce development, enforcement and institutional accountability.
As NAFDAC pursues Maturity Level 4 and WHO-Listed Authority status, the long-term test will be the Agency’s ability to translate regulatory progress into consistent improvements in the quality, safety and availability of medical products for Nigerians and the wider African population.